



## **FLOW MRD monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34<sup>+</sup>CD38<sup>low</sup>CD19<sup>+</sup> in B lineage childhood acute lymphoblastic leukemia**

by Kerrie Wilson, Marian Case, Lynne Minto, Simon Bailey, Nick Bown, Jenny Jesson, Sarah Lawson, Josef Vormoor, and Julie A.E. Irving

*Haematologica* 2009 [Epub ahead of print]

doi:10.3324/haematol.2009.011726

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. This paper will now undergo editing, proof correction and final approval by the authors. Please note that during this production process changes may be made, and errors may be identified and corrected. The final version of the manuscript will appear both in the print and the online journal. All legal disclaimers that apply to the journal also pertain to this production process.*

Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, [www.haematologica.org](http://www.haematologica.org)) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing ([www.doaj.org](http://www.doaj.org)). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature. Haematologica is the official organ of the European Hematology Association ([www.ehaweb.org](http://www.ehaweb.org)).

Support Haematologica and Open Access Publishing by becoming a member of the European Hematology Association (EHA) and enjoying the benefits of this membership, which include free participation in the online CME program

Supplementary Table 1

Patient No.	Cytogenetic Group	CD34 expression	CD10 expression	CD38 Expression at presentation (relative to normal progenitors)
754	High Hyperdiploid	Bi-modal	Positive	Overlap
771	High Hyperdiploid	Bi-modal	Positive	Overlap
748	High Hyperdiploid	Bi-modal	Positive	Under
815	High Hyperdiploid	Bi-modal	Positive	Under
773	High Hyperdiploid	Positive	Positive	Overlap
726	High Hyperdiploid	Positive	Positive	Under
829	High Hyperdiploid	Positive	Low	Under
835	High Hyperdiploid	Bi-modal	Positive	Under
725	Not Known	Bi-modal	Positive	Normal
727	Other	Bi-modal	Positive	Normal
730	Other	Negative	Positive	Normal
736	Other	Positive	Positive	Normal
737	Other	Positive	Positive	Normal
752	Other	Bi-modal	Positive	Normal
779	Other	Bi-modal	Positive	Normal
784	Other	Bi-modal	Low	Normal
786	Other	Positive	Positive	Normal
790	Other	Positive	Positive	Normal
791	Other	Bi-modal	Low	Normal
792	Other	Positive	Positive	Normal
803	Other	Bi-modal	Low	Normal
827	Other	Bi-modal	Low	Normal
831	Other	Positive	Low	Normal
833	Other	Bi-modal	Positive	Normal
724	Other	Bi-modal	Positive	Overlap
729	Other	Positive	Positive	Overlap
812	Other	Bi-modal	Positive	Overlap
731	Other	Positive	Positive	Under
770	Ph+	Bi-modal	Positive	Under
776	Other	Bi-modal	Positive	Under
778	Other	Bi-modal	Positive	Under
782	Other	Positive	Low	Under
787	Other	Bi-modal	Positive	Under
788	Other	Positive	Low	Under
793	Other	Positive	Positive	Under
810	Other	Bi-modal	Positive	Under
824	Other	Bi-modal	Positive	Under
825	Other	Bi-modal	Low	Under
848	TEL/AML	Bi-modal	Positive	Overlap
723	TEL/AML	Positive	Positive	Under
733	TEL/AML	Bi-modal	Positive	Under
749	TEL/AML	Bi-modal	Positive	Under
751	TEL/AML	Bi-modal	Positive	Under
777	TEL/AML	Bi-modal	Positive	Under
798	TEL/AML	Bi-modal	Positive	Under
828	TEL/AML	Bi-modal	Positive	Under
837	TEL/AML	Bi-modal	Positive	Under
847	TEL/AML	Bi-modal	Positive	Under

CD34 <sup>+</sup> CD38 <sup>Low</sup> CD19 <sup>+</sup> population at presentation	Frequency of the CD34 <sup>+</sup> CD38 <sup>Low</sup> CD19 <sup>+</sup> population in the blast population at presentation	D28 MRD
Negative		Positive (0.07%)
Negative		Negative
Negative		Negative
Positive	2,3	Negative
Positive	0,7	Positive (0.819%)
Positive	74,3	Positive (1.49%)
Positive	0,8	Negative
Positive	3,3	Positive (0.36%)
Negative		Negative
Negative		No LAIP
Negative		Indeterminate
Negative		Not done
Negative		No LAIP
Negative		Indeterminate
Negative		Indeterminate
Negative		Negative
Negative		Negative
Negative		Not done
Negative		Not done
Negative		No LAIP
Negative		Negative
Negative		Negative
Negative		Negative
Negative		Negative
Positive	0,6	Positive (2.4%)
Positive	0,5	Negative
Positive	0,2	Negative
Positive	10,0	Indeterminate
Positive	72,3	Positive (4.22%)
Positive	4,5	Negative
Positive	80,3	Positive (3.7%)
Positive	8,8	Negative
Positive	5,6	Positive (26.7%)
Positive	13,9	Negative
Positive	10,5	Not done
Positive	30,8	Negative
Positive	17,8	Positive (57.12%)
Positive	18,0	Positive (1.35%)
Positive	0,2	Indeterminate
Positive	14,4	Negative
Positive	1,1	Not done
Positive	11,8	Negative
Positive	3,6	Negative
Positive	10,9	Negative
Positive	2,1	Positive (0.014%)
Positive	0,6	Negative
Positive	1,2	Positive (0.01%)
Positive	7,8	Negative

Supplementary Table 2

Patient No.	Cytogenetic Group	Age	Presenting white cell count (x10 <sup>9</sup> /L)	Risk group
L726	High Hyperdiploid	15,3	Not Known	B
L773	High Hyperdiploid	3,8	2	A
L787	Other	19,4	11,6	B
L825	Other	14,7	100	B
L778	Other	4,4	19,1	A
L770	Ph+	7,9	31,3	A then C
L824	Other	16	20	B

Induction Therapy

Peg Asparaginase/Dexamethasone/Vincristine/Daunorubicin/Methotrexate (IT)

Peg Asparaginase/Dexamethasone/Vincristine/Methotrexate (IT)

Peg Asparaginase/Dexamethasone/Vincristine/Daunorubicin/Methotrexate (IT)

Peg Asparaginase/Dexamethasone/Vincristine/Daunorubicin/Methotrexate (IT)

Peg Asparaginase/Dexamethasone/Vincristine/Methotrexate (IT)

Peg Asparaginase/Dexamethasone/Vincristine/Daunorubicin/Methotrexate (IT)

Peg Asparaginase/Dexamethasone/Vincristine/Daunorubicin/Methotrexate (IT)